Dune Medical Raises $12.3M in Financing
Summary
Dune Medical Devices, a Caesarea, Israel-based developer of RF Spectroscopy technology to detect microscopic residual cancer, closed a $12.3m financing round.The company will use the funds to establish a new standard of care with its existing MarginProbe System and to further develop their RF spectroscopy platform into other applications.Led by CEO Lori Chmura, Dune Medical is based upon proprietary radiofrequency (RF) spectroscopy platform which will be applied to a variety of other cancers following the application of its first marketed product, the MarginProbe System.In addition to use during breast cancer surgery, Dune’s RF spectroscopy platform is being explored for other applications and disease sites.In August 2016, the company received a €3m EU Horizon 2020 grant to support the continued development of its RF spectroscopy based biopsy system.